Why Healthcare Is Outperforming the Broader Market

While the Nifty 50 is down 14% so far in 2026, the Nifty Pharma index is down only by 2% in the same period. That is not a coincidence. It is a pattern that mutual fund managers noticed before most retail investors did.

This blog breaks down why so many diversified mutual funds are increasing their bet on healthcare, what data is driving this move, and what you, as an investor, should think about before reading too much into it.

How the Nifty Pharma Index Has Performed Versus the Nifty 50

Before getting into the why, look at the numbers side by side.

As on 31th March 2026

The Nifty Pharma index has beaten the Nifty 50 across all three time periods shown here. The YTD gap is especially sharp. The broader market is in negative territory, while healthcare is holding up.

This is not surprising if you understand what kind of sector healthcare is in. People do not stop buying medicines or visiting hospitals when the stock market falls or the economy slows down. That stability in business earnings is what makes healthcare a "defensive" sector. Stocks in defensive sectors tend to fall less during market downturns compared to sectors like real estate, auto, or consumer goods.

Why Are So Many Mutual Funds Moving Into Healthcare?

Fund managers have taken note of this. The sector now accounts for 7.3% of total mutual fund portfolios in India. For context, the benchmark BSE 200 has only 5.65% weight in this sector, which means funds are holding meaningfully more than what the benchmark suggests.

Key stocks that these funds are holding include Sun Pharmaceutical Industries, Dr Reddy's Labs, Biocon, and Apollo Hospitals.

The overweight position simply means fund managers believe this sector will do better than the rest of the market over the near term. They are putting more money here than the benchmark would require them to.

What Is Actually Driving Growth in This Sector

The defensive argument alone does not explain why fund managers are so bullish right now. There are specific structural reasons the healthcare sector in India is growing.

1. India's Manufacturing Edge and the China Plus One Factor

Many global companies are looking to reduce their dependence on China for manufacturing. India has emerged as a major alternative, especially in pharmaceuticals. According to McKinsey, India has more than 750 facilities approved by the US FDA and more than 2,050 plants certified by the World Health Organisation for good manufacturing practices. India has one of the largest concentrations of regulatory-compliant pharma manufacturing facilities outside the US. When global companies want a reliable, cost-efficient supplier outside China, India is often the first name on the list.

2. India Is Moving Beyond Generic Medicines

For decades, India was known mainly as a manufacturer of generic drugs, which are cheaper copies of medicines whose patents have expired. That is changing. Indian firms are now entering more complex categories like biosimilars, injectables, and ADCs. Indian firms are gaining ground in biosimilars and other complex drug categories, supported by stronger R&D and manufacturing capabilities. The number of drugs in India's innovation pipeline has also grown from roughly 270 in 2015 to about 450 in 2024. That is a 1.5 times increase in less than a decade. This shift from low-margin generics to higher-value products improves the long-term profitability of Indian pharma companies.

3. The Hospital Sector Is Expanding Rapidly

This is not just about medicines. The hospital business in India is growing fast too. According to KPMG, the multi-speciality hospital market in India was valued at INR 6,300 billion in 2024 and is projected to reach INR 9,800 billion by 2028. That is a compounded annual growth rate of around 12%. As more Indians move to cities and middle-class incomes rise, demand for quality hospital care is increasing. Large hospital chains are expanding their networks to meet this demand.

4. Health Insurance Coverage and Premiums Are Rising

More Indians are now covered under health insurance than ever before. According to the Observer Research Foundation, based on IRDAI's Annual Report for 2024-25, health insurance has become the single largest segment within non-life insurance in India. It now contributes 41.42% of all gross direct premiums collected by general and health insurers. When more people have health insurance, they are more likely to access formal healthcare, which directly benefits hospital chains and diagnostic companies.

Which Diversified Funds Currently Have Higher Healthcare Allocation

One important thing to note is that these are not sectoral or thematic funds. These are regular diversified equity funds that have chosen to give more weight to healthcare as part of their overall portfolio strategy.

Source: Mutual Fund Factsheets

A 15% allocation to a single sector within a diversified fund is quite significant. It shows that the fund manager has a strong conviction in healthcare's near-term performance. However, if healthcare underperforms, it will have a noticeable impact on that fund's overall returns.

If you are already invested in any of these funds, your portfolio already has some exposure to healthcare, whether you planned for it or not.

Things to Keep in Mind Before You Act on This

This section matters as much as everything above it.

• Regulatory risk is real. Indian pharma companies, especially those exporting to the US, face strict scrutiny from the US FDA. A single warning letter or import alert can cause a stock to fall sharply. This risk does not go away just because the sector is doing well right now.
• Hospital stocks carry their own risks. Hospitals are expensive businesses to run and expand. Regulatory issues around pricing and treatment costs can affect profitability. Apollo Hospitals and similar stocks are already trading at high valuations, which limits how much upside may still be available.
• Past outperformance does not guarantee future returns. The Nifty Pharma index has done well YTD and over one year. But it has also gone through long periods of underperformance. Between 2015 and 2020, the Nifty Pharma index delivered very poor returns. Sector cycles turn.
• Fund allocations change. What a fund holds today can be different six months from now. Fund managers are not making a permanent commitment to healthcare. If their outlook changes, they will reduce the allocation. You should not assume that because a fund is overweight today, it will stay that way.
• This is still a wait-and-watch period. There is ongoing global uncertainty. The full impact of trade policy changes, currency movements, and domestic regulatory shifts is not yet clear. Which sectors and funds will come out ahead will only become visible over time.

What Should You Take Away From This

The move toward healthcare by mutual fund managers is backed by real data, both at the market level and at the sector fundamentals level. Defensive characteristics, India's manufacturing strength, rising hospital demand, and growing insurance coverage all make a reasonable case for this sector.

But no sector outperforms in a straight line, and what looks smart today can look premature in hindsight. If you are a long-term investor in a diversified equity fund, this shift in allocation is something to be aware of, not something to chase separately by rushing to buy a pharma fund. Let your fund manager do their job. Your job is to stay invested and not react to short-term sector trends.

Disclaimer: The content is meant for education and general information purposes only.  Past performance is not indicative of future returns. Mutual Funds are non-exchange traded products, and INDstocks is merely acting as a mutual fund distributor. All disputes with respect to distribution activity, would not have access to the exchange investor redressal forum or arbitration mechanism. Mutual Fund investments are subject to market risks, read all scheme related documents carefully before investing. INDstocks Private Limited (formerly known as INDmoney Private Limited) 616, Level 6, Suncity Success Tower, Sector 65, Gurugram, 122005, SEBI Stock Broking Registration No: INZ000305337, Trading and Clearing Member of NSE (90267, M70042) and BSE, BSE StarMF (6779), AMFI Registration No: ARN-254564, SEBI Depository Participant Reg. No. IN-DP-690-2022, Depository Participant ID: CDSL 12095500, Research Analyst Registration No. INH000018948 BSE RA Enlistment No. 6428.